Oleanonic acid (Synonyms: 3-Oxooleanolic acid)

Name: Oleanonic acid
Brand: MedChemExpress
SKU: HY-N1487
Rating: 4.5 (1 reviews)

Cat. No.: HY-N1487 Purity: 99.63%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Oleanonic acid (3-Oxooleanolic acid) is an orally available triterpene that has anti-inflammatory and insecticidal properties. In vitro, oleanonic acid can improve oxidative stress, autophagy defects, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress induced by Amyloid-β, and in vivo, it can alleviate myocardial hypertrophy in rats.

For research use only. We do not sell to patients.

Oleanonic acid Chemical Structure

CAS No. : 17990-42-0

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 66	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 66	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 60	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Oleanonic acid:

Oleanonic acid (Standard) Get quote

1 Publications Citing Use of MCE Oleanonic acid

•Pharmacol Res. 2024 May 9:204:107208. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 20 μg/mL Compound: Oleanonic acid	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
A549	IC₅₀	49.5 μM Compound: 4a	Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
BJ	IC₅₀	> 50 μM Compound: 4a	Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay Cytotoxicity against human BJ cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
Ca9-22	IC₅₀	18.04 μg/mL Compound: Oleanonic acid	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
CCRF-CEM	IC₅₀	15.1 μM Compound: 4a	Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay Cytotoxicity against human CCRF-CEM cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
H9	EC₅₀	0.11 μg/mL Compound: 27	Cytotoxicity against mock-infected human H9 cells after 4 days Cytotoxicity against mock-infected human H9 cells after 4 days	[PMID: 9748372]
H9	IC₅₀	0.8 μg/mL Compound: 27	Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA	[PMID: 9748372]
HCT-116	IC₅₀	> 50 μM Compound: 4a	Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against p53 knockout human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
HCT-116	IC₅₀	45.1 μM Compound: 4a	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
Hep 3B2	IC₅₀	> 20 μg/mL Compound: Oleanonic acid	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	> 20 μg/mL Compound: Oleanonic acid	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
J774.A1	IC₅₀	38.8 μM Compound: 3	Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
J774.A1	IC₅₀	87.72 μM Compound: 3	Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control	[PMID: 25113933]
K562	IC₅₀	> 50 μM Compound: 4a	Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
MCF7	IC₅₀	> 20 μg/mL Compound: Oleanonic acid	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21106454]
MDA-MB-231	IC₅₀	> 20 μg/mL Compound: Oleanonic acid	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21106454]
MRC5	IC₅₀	> 50 μM Compound: 4a	Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay Cytotoxicity against human MRC5 cells incubated for 72 hrs by MTS assay	[PMID: 31677446]
RAW264.7	IC₅₀	38.5 μM Compound: 3	Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
RAW264.7	IC₅₀	89.6 μM Compound: 3	Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control	[PMID: 25113933]
U2OS	IC₅₀	48.5 μM Compound: 4a	Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells incubated for 72 hrs by MTS assay	[PMID: 31677446]

In Vitro

Oleanonic acid inhibits HIV-1 infection in PBMCs in vitro, with EC₅₀ values for naturally infected PBMCs and monocytes/macrophages being 22.7 mM, 24.6 mM, and 57.4 mM, respectively. Furthermore, it can inhibit the production of leukotriene B4 by mouse peritoneal leukocytes, with an IC₅₀ of 17 μM^[2].
Oleanonic acid has strong anti-insect activity against Rhipicephalus (Kreyszig) and Amazon ticks, with IC₅₀ values of 18.5 µM and 29.9 µM^[3].
Oleanonic acid (0-45 μM, 24 h) inhibits the increase of NF-κB transcription activity in cardiomyocytes treated with phenylephrine (PE) and reduces the mRNA expression of hypertrophic genes like atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) in a dose-dependent manner^[4].
Oleanonic acid (15 μM, 24 h) inhibits the phosphorylation of protein kinase Cζ (PKCζ) at the Thr410 site in cardiomyocytes, subsequently reducing NF-κB activation in PE-treated cardiomyocytes^[4].
Oleanonic acid (1-5 μM, 48 h) reduces APP expression in SH-SY5Y cells, lessens damage induced by oxidative stress, repairs autophagy defects, and inhibits ferroptosis^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[4]

Cell Line:	NRCMs
Concentration:	0, 5, 15, 45 μM
Incubation Time:	24 h
Result:	Inhibited NF-κB transcriptional activity and reduced the expression of hypertrophic genes such as Atrial Natriuretic Factor (ANF) and Brain Natriuretic Peptide (BNP).

Western Blot Analysis^[4]

Cell Line:	NRCMs
Concentration:	15 μM
Incubation Time:	24 h
Result:	Inhibited the phosphorylation of the Thr410 site protein kinase PKCζ, and suppressed NF-κB.

Western Blot Analysis^[5]

Cell Line:	SH-SY5Y, SH-SY5Y-APP
Concentration:	1, 2.5, 5 μM
Incubation Time:	48 h
Result:	Reduced APP expression, inhibited mTOR phosphorylation, increased autophagy markers ATG5 and LC3-II, suppressed Nrf2 and HO-1, and restored the levels of GPX4, NCOA, and COX2.

In Vivo

Oleanonic acid (15-45 mg/kg, oral, daily, 8 weeks) inhibits the PKCζ-NF-κB signaling pathway in rats and effectively improves cardiac hypertrophy^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	AAC rats^[4]
Dosage:	15, 45 mg/kg; daily; 8 weeks
Administration:	Oral
Result:	Reduced heart size and visibly decreased the thickness of the left ventricular wall, and in a dose-dependent manner, there was also a reduction in myocardial cell diameter and the heart weight to body weight ratio (HW/BW) under 400x HE staining.

Molecular Weight

454.68

Formula

C₃₀H₄₆O₃

CAS No.

17990-42-0

Appearance

Solid

Color

White to off-white

SMILES

CC1(C)C(CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])CC(C)(C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H])=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (109.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ mg/mL

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1993 mL	10.9967 mL	21.9935 mL
5 mM	0.4399 mL	2.1993 mL	4.3987 mL
10 mM	0.2199 mL	1.0997 mL	2.1993 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.50 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.63%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (252 KB) HNMR (286 KB) RP-HPLC (244 KB) MS (72 KB)

Handling Instructions (2659 KB)

References

[1]. Giner-Larza EM et al.Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.Eur J Pharmacol.Sep 28;428(1):137-43.doi:10.1016/S0014-2999(01)01290-0(2001) [Content Brief]

[2]. Fabio Mengoni.Anti-HIV Activity of Oleanolic Acid on Infected Human Mononuclear Cells.Planta Med 68(2): 111-114.DOI: 10.1055/s-2002-20256(2002) [Content Brief]

[3]. Cristiano S. FUNARI, et al. Oleanonic acid from Lippia lupulina (Verbenaceae).shows strong in vitro antileishmanial and antitrypanosomal activity. Acta Amazonica. 46 (4) .Oct-Dec 2016

[4]. Hui Gao, et al. Oleanonic acid ameliorates pressure overload-induced cardiac hypertrophy in rats: The role of PKCζ-NF-κB pathway. Mol Cell Endocrinol. 2018 Jul 15:470:259-268. [Content Brief]

[5]. Liqing Tao, et al. Oleanonic acid ameliorates mutant Aβ precursor protein-induced oxidative stress, autophagy deficits, ferroptosis, mitochondrial damage, and ER stress in vitro. Biochim Biophys Acta Mol Basis Dis. 2024 Dec;1870(8):167459. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1993 mL	10.9967 mL	21.9935 mL	54.9837 mL
	5 mM	0.4399 mL	2.1993 mL	4.3987 mL	10.9967 mL
	10 mM	0.2199 mL	1.0997 mL	2.1993 mL	5.4984 mL
	15 mM	0.1466 mL	0.7331 mL	1.4662 mL	3.6656 mL
	20 mM	0.1100 mL	0.5498 mL	1.0997 mL	2.7492 mL
	25 mM	0.0880 mL	0.4399 mL	0.8797 mL	2.1993 mL
	30 mM	0.0733 mL	0.3666 mL	0.7331 mL	1.8328 mL
	40 mM	0.0550 mL	0.2749 mL	0.5498 mL	1.3746 mL
	50 mM	0.0440 mL	0.2199 mL	0.4399 mL	1.0997 mL
	60 mM	0.0367 mL	0.1833 mL	0.3666 mL	0.9164 mL
	80 mM	0.0275 mL	0.1375 mL	0.2749 mL	0.6873 mL
	100 mM	0.0220 mL	0.1100 mL	0.2199 mL	0.5498 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Oleanonic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Oleanonic acid (Synonyms: 3-Oxooleanolic acid)

Customer Review

Other Forms of Oleanonic acid:

1 Publications Citing Use of MCE Oleanonic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Oleanonic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Oleanonic acid (Synonyms: 3-Oxooleanolic acid)

Customer Review

Other Forms of Oleanonic acid:

Oleanonic acid Related Antibodies

1 Publications Citing Use of MCE Oleanonic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Oleanonic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Oleanonic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report